These first-in-human data demonstrated the safety and tolerability of UCART19, resulting in an 83% complete remission rate across the adult and pediatric patient population.
The CALM study (UCART19 in Advanced Lymphoid Malignancies) is an open label, dose-escalation study designed to evaluate the safety, tolerability, and anti-leukemic activity of UCART19 in adult patients with R/R B-ALL.
Five out seven patients treated achieved molecular remission, defined by negative minimal residual disease (MRD), a measurement of the number of residual leukemic cells that remain after treatment, at Day 28 post UCAR19.
The PALL (Pediatric Acute Lymphoblastic Leukemia) study is a phase 1, open label study designed to evaluate the safety and ability of UCART19 to induce molecular remission defined by MRD negativity at Day 28 to enable allogeneic stem cell transplantation in pediatric patients with high-risk R/R B-ALL.
Results showed all five children achieved MRD negativity, enabling them to proceed to allogeneic stem cell transplant.
Servier is the sponsor of both studies that are active in Europe and the United States.
UCART19, an allogeneic CAR T-cell product candidate being developed for treatment of CD19-expressing hematological malignancies, is gene edited with Cellectis' Talen technology.
Servier, governed by a non-profit foundation, has an international presence in 148 countries, a turnover of EUR4 bn in 2016, and employs 21,000 people worldwide.
It reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. The company focuses on five areas: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancers and diabetes, in addition to activities in high-quality generic drugs.
Pfizer discovers, develops, manufactures, and sells healthcare products worldwide. Its global portfolio includes medicines and vaccines as well as consumer health care products.
The company collaborates with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world.
Cellectis is focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). Using its life-science-focused, pioneering genome engineering technologies, the company's goal is to create innovative products in multiple fields and with various target markets.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling